Literature DB >> 10588940

Oxidants and antioxidants in atherogenesis. An appraisal.

S Parthasarathy1, N Santanam, S Ramachandran, O Meilhac.   

Abstract

Oxidized low density lipoprotein (Ox-LDL) has a plethora of components that are not present in native LDL. Their presence and quantity depends on the nature, type, and extent of oxidation. Lipids esterified to oxidized fatty acids are the major components formed during the early phase of oxidation and these show a number of proatherogenic properties in in vitro cell culture systems. Recently, evidence has been forthcoming to suggest that some of these oxidized lipids also could elicit "antioxidant;-antiatherogenic" responses from cells. Moreover, some of the cellular effects of Ox-LDL that were previously interpreted as atherogenic could also be reinterpreted to suggest an antiatherogenic cellular response. In addition to the above, the antioxidants that are carried in lipoproteins could have anomalous behavior attributable to their metabolism, ability to be internalized by arterial cells, and the presence of oxidative systems that could render them prooxidants. In conclusion, there are numerous contributing factors that need to be studied and understood before antioxidant therapy becomes an option for the treatment for cardiovascular diseases.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10588940

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  35 in total

Review 1.  Did the antioxidant trials fail to validate the oxidation hypothesis?

Authors:  S Parthasarathy; N Khan-Merchant; M Penumetcha; B V Khan; N Santanam
Journal:  Curr Atheroscler Rep       Date:  2001-09       Impact factor: 5.113

Review 2.  Oxidative stress in cardiovascular disease.

Authors:  S Parthasarathy; N Khan-Merchant; M Penumetcha; N Santanam
Journal:  J Nucl Cardiol       Date:  2001 May-Jun       Impact factor: 5.952

3.  Physical inactivity and cardiovascular risk: baseline observations from men and premenopausal women.

Authors:  Mahdi Garelnabi; Emir Veledar; Jerome Abramson; Jill White-Welkley; Nalini Santanam; William Weintraub; Sampath Parthasarathy
Journal:  J Clin Lab Anal       Date:  2010       Impact factor: 2.352

4.  OxLDL induces endothelial dysfunction and death via TRAF3IP2: inhibition by HDL3 and AMPK activators.

Authors:  Anthony J Valente; Anand M Irimpen; Ulrich Siebenlist; Bysani Chandrasekar
Journal:  Free Radic Biol Med       Date:  2014-02-20       Impact factor: 7.376

Review 5.  Oxidized low-density lipoprotein.

Authors:  Sampath Parthasarathy; Achuthan Raghavamenon; Mahdi Omar Garelnabi; Nalini Santanam
Journal:  Methods Mol Biol       Date:  2010

6.  Alpha-tocopherol is ineffective in preventing the decomposition of preformed lipid peroxides and may promote the accumulation of toxic aldehydes: a potential explanation for the failure of antioxidants to affect human atherosclerosis.

Authors:  Achuthan Raghavamenon; Mahdi Garelnabi; Sainath Babu; Alex Aldrich; Dmitry Litvinov; Sampath Parthasarathy
Journal:  Antioxid Redox Signal       Date:  2009-06       Impact factor: 8.401

7.  Antioxidant and hypolipidemic activity of Kumbhajatu in hypercholesterolemic rats.

Authors:  Rumi Ghosh; Parag P Kadam; Vilasrao J Kadam
Journal:  Int J Ayurveda Res       Date:  2010-07

8.  Effect of Erythrina variegata seed extract on hyperlipidemia elicited by high-fat diet in wistar rats.

Authors:  G Balamurugan; A Shantha
Journal:  J Pharm Bioallied Sci       Date:  2010-10

Review 9.  HDL and endothelial protection.

Authors:  A Tran-Dinh; D Diallo; S Delbosc; L Maria Varela-Perez; Q B Dang; B Lapergue; E Burillo; J B Michel; A Levoye; J L Martin-Ventura; O Meilhac
Journal:  Br J Pharmacol       Date:  2013-06       Impact factor: 8.739

10.  Red beet (Beta vulgaris L.) leaf supplementation improves antioxidant status in C57BL/6J mice fed high fat high cholesterol diet.

Authors:  Jeung Hee Lee; Chan Wook Son; Mi Yeon Kim; Min Hee Kim; Hye Ran Kim; Eun Shil Kwak; Sena Kim; Mee Ree Kim
Journal:  Nutr Res Pract       Date:  2009-06-30       Impact factor: 1.926

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.